Developer docs
API playgroundTry for free, no card

Search company profiles

89bio

Full company profile

uuid0000955

Namestring
89bio
Legal namestring
89bio, Inc.
Websiteurl
89bio.com
Company typeenum
Public
Founded yearint
2018
Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
FGF21 analogs, MASH therapeutics, liver disease drugs, cardiometabolic biopharmaceuticals, glycoPEGylation platform
Industry3 codes
PRIMARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIACAE
Gastroenterology Specialty Pharmaceuticals
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceutical Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Biopharmaceutical Product Revenue
TypeOne Time License
Description

As a clinical-stage biopharmaceutical company, 89bio was pre-revenue and did not have any approved products. All revenue would come from future product sales if pegozafermin receives regulatory approval. The company was acquired by Roche in late 2025 before commercializing any products.

89bio.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

89bio developed a single clinical-stage therapeutic candidate, pegozafermin (BIO89-100), an investigational glycoPEGylated FGF21 analog being evaluated in Phase 3 trials for metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). The asset is designed to act as a master metabolic regulator targeting energy expenditure, glucose metabolism, and lipid metabolism across multiple tissues. The company had no approved or commercialized products prior to its acquisition by Roche in late 2025.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

89bio is a clinical-stage biopharmaceutical company dedicated to developing and delivering innovative therapies to treat patients with liver and cardiometabolic diseases. The company's sole product candidate is pegozafermin (BIO89-100), an investigational FGF21 analog developed using proprietary glycoPEGylation technology. Pegozafermin is currently in Phase 3 clinical development for two indications: MASH (metabolic dysfunction-associated steatohepatitis) through the ENLIGHTEN trials, and severe hypertriglyceridemia (SHTG) through the ENTRUST trial. The company was acquired by Roche in late 2025.

Product and service1 record
1Pegozafermin (BIO89-100)
CategoryClinical-stage biopharmaceutical therapeutic candidate
Description

Pegozafermin (BIO89-100) is an investigational glycoPEGylated FGF21 analog being developed for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). It is intended for adult patients with progressive liver disease and cardiometabolic conditions where approved or effective treatment options are limited.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-18
Description

Roche entered into a definitive agreement to acquire 89bio for approximately $2.4 billion in cash with total deal value of up to $3.5 billion including contingent payments. The acquisition strengthened Roche's portfolio in cardiovascular, renal, and metabolic diseases, particularly for the treatment of MASH. The transaction was expected to close in Q4 2025, pending regulatory approvals. Roche completed the acquisition of 89bio, integrating the company and its employees into Roche's pharmaceuticals division.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Inventiva is developing lanifibranor, a pan-PPAR agonist for MASH, competing in the same Phase 3 regulatory race against pegozafermin's ENLIGHTEN program.

TypeDirect peer
Description

Madrigal developed Rezdiffra (resmetirom), the first FDA-approved MASH therapy. It is the direct competitive benchmark for any new MASH entrant including pegozafermin, sharing the same prescriber base (hepatologists/endocrinologists) and treatment setting.

TypeBroad incumbent
Description

Novo Nordisk's semaglutide has generated positive MASH Phase 3 data and Ozempic/Wegovy dominate the cardiometabolic landscape that pegozafermin targets, creating indirect but substantial competitive pressure on adoption.

TypeBroad incumbent
Description

Lilly's tirzepatide (Mounjaro/Zepbound) is being investigated in MASH and the broader tirzepatide franchise addresses obesity and cardiometabolic disease, making Lilly an incumbent competitor with overlapping physician call points and patient population.

TypeDirect peer
Description

Viking is advancing VK2809 (oral thyroid receptor agonist) and VK2735 (dual GLP-1/GIP) for MASH and obesity-related metabolic disease, positioning as another mid-stage MASH competitor with adjacent cardiometabolic pipeline overlap.

6Boehringer Ingelheim (with Zealand Pharma)
TypeBroad incumbent
Description

Boehringer Ingelheim is co-developing survodutide (a GLP-1/glucagon dual agonist) with Zealand Pharma for MASH and obesity, representing a broader-incumbent entrant with significant cardiometabolic commercial infrastructure overlapping 89bio's target market.

TypeEmerging player
Description

Terns is developing TERN-501 (a thyroid receptor agonist) and other MASH candidates, representing a smaller emerging competitor focused on the same liver indication that pegozafermin targets.

TypeBroad incumbent
Description

Pfizer has publicly invested in MASH and broader cardiometabolic programs (e.g., via partnerships and internal candidates), representing a large incumbent with the commercial scale to compete in the same prescriber space post any pegozafermin approval.

TypeDirect peer
Description

Akero is developing efruxifermin, an FGF21 analog (Fc fusion) for MASH, directly competing with 89bio's pegozafermin on the same mechanism and primary indication. Closest mechanistic and clinical competitor.

TypeEmerging player
Description

Galmed (now Lipocine) has historically pursued MASH/NASH therapies with aramchol, providing an early-stage peer in the same liver disease space, though with a different mechanism than pegozafermin.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

89bio

Biopharmaceutical Therapeutics89bio.com

89bio firmographics

Firmographics
Name
89bio
Legal name
89bio, Inc.
Website
https://89bio.com
Company type
Public
Founded year
2018
Operating status
Acquired
Headcount range
101–250 employees
Ownership category
akta.pro rank

89bio industry classification

Industry
Product category
Biopharmaceutical Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIACAE
Gastroenterology Specialty Pharmaceuticals

Keywords

  • FGF21 analogs
  • MASH therapeutics
  • Liver disease drugs
  • Cardiometabolic biopharmaceuticals
  • GlycoPEGylation platform

Where 89bio is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices2 records

Markets served

89bio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Biopharmaceutical Product Revenue: As a clinical-stage biopharmaceutical company, 89bio was pre-revenue and did not have any approved products. All revenue would come from future product sales if pegozafermin receives regulatory approval. The company was acquired by Roche in late 2025 before commercializing any products.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

89bio product offering

Product offering

Core offering

89bio developed a single clinical-stage therapeutic candidate, pegozafermin (BIO89-100), an investigational glycoPEGylated FGF21 analog being evaluated in Phase 3 trials for metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). The asset is designed to act as a master metabolic regulator targeting energy expenditure, glucose metabolism, and lipid metabolism across multiple tissues. The company had no approved or commercialized products prior to its acquisition by Roche in late 2025.

Product overview

89bio is a clinical-stage biopharmaceutical company dedicated to developing and delivering innovative therapies to treat patients with liver and cardiometabolic diseases. The company's sole product candidate is pegozafermin (BIO89-100), an investigational FGF21 analog developed using proprietary glycoPEGylation technology. Pegozafermin is currently in Phase 3 clinical development for two indications: MASH (metabolic dysfunction-associated steatohepatitis) through the ENLIGHTEN trials, and severe hypertriglyceridemia (SHTG) through the ENTRUST trial. The company was acquired by Roche in late 2025.

Differentiator

Problem solved

Functional benefit

Products and services

  • Pegozafermin (BIO89-100) Pegozafermin (BIO89-100) is an investigational glycoPEGylated FGF21 analog being developed for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). It is intended for adult patients with progressive liver disease and cardiometabolic conditions where approved or effective treatment options are limited.

Companies that use 89bio

Customer profile

Segments2 records

Ideal customer profiles2 records

89bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

89bio partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • RochecoreStrategic or Co-development Partner · 18 September 2025Roche entered into a definitive agreement to acquire 89bio for approximately $2.4 billion in cash with total deal value of up to $3.5 billion including contingent payments. The acquisition strengthened Roche's portfolio in cardiovascular, renal, and metabolic diseases, particularly for the treatment of MASH. The transaction was expected to close in Q4 2025, pending regulatory approvals. Roche completed the acquisition of 89bio, integrating the company and its employees into Roche's pharmaceuticals division.

Scale indicators5 records

Recent moves8 records

Expansion highlights5 records

89bio competitors and assessment

Company assessment

Direct peers

  • Inventiva: Inventiva is developing lanifibranor, a pan-PPAR agonist for MASH, competing in the same Phase 3 regulatory race against pegozafermin's ENLIGHTEN program.
  • Madrigal Pharmaceuticals: Madrigal developed Rezdiffra (resmetirom), the first FDA-approved MASH therapy. It is the direct competitive benchmark for any new MASH entrant including pegozafermin, sharing the same prescriber base (hepatologists/endocrinologists) and treatment setting.
  • Viking Therapeutics: Viking is advancing VK2809 (oral thyroid receptor agonist) and VK2735 (dual GLP-1/GIP) for MASH and obesity-related metabolic disease, positioning as another mid-stage MASH competitor with adjacent cardiometabolic pipeline overlap.
  • Akero Therapeutics: Akero is developing efruxifermin, an FGF21 analog (Fc fusion) for MASH, directly competing with 89bio's pegozafermin on the same mechanism and primary indication. Closest mechanistic and clinical competitor.

Broad incumbents

  • Novo Nordisk: Novo Nordisk's semaglutide has generated positive MASH Phase 3 data and Ozempic/Wegovy dominate the cardiometabolic landscape that pegozafermin targets, creating indirect but substantial competitive pressure on adoption.
  • Eli Lilly: Lilly's tirzepatide (Mounjaro/Zepbound) is being investigated in MASH and the broader tirzepatide franchise addresses obesity and cardiometabolic disease, making Lilly an incumbent competitor with overlapping physician call points and patient population.
  • Boehringer Ingelheim (with Zealand Pharma): Boehringer Ingelheim is co-developing survodutide (a GLP-1/glucagon dual agonist) with Zealand Pharma for MASH and obesity, representing a broader-incumbent entrant with significant cardiometabolic commercial infrastructure overlapping 89bio's target market.
  • Pfizer: Pfizer has publicly invested in MASH and broader cardiometabolic programs (e.g., via partnerships and internal candidates), representing a large incumbent with the commercial scale to compete in the same prescriber space post any pegozafermin approval.

Emerging players

  • Terns Pharmaceuticals: Terns is developing TERN-501 (a thyroid receptor agonist) and other MASH candidates, representing a smaller emerging competitor focused on the same liver indication that pegozafermin targets.
  • Galmed Pharmaceuticals: Galmed (now Lipocine) has historically pursued MASH/NASH therapies with aramchol, providing an early-stage peer in the same liver disease space, though with a different mechanism than pegozafermin.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

89bio social profiles

Digital presence

89bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

89bio leadership team

Management profile

Number of profiles

Profiles5 records

89bio funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

89bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 89bio

What does 89bio do?

89bio developed a single clinical-stage therapeutic candidate, pegozafermin (BIO89-100), an investigational glycoPEGylated FGF21 analog being evaluated in Phase 3 trials for metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). The asset is designed to act as a master metabolic regulator targeting energy expenditure, glucose metabolism, and lipid metabolism across multiple tissues. The company had no approved or commercialized products prior to its acquisition by Roche in late 2025.

Is 89bio a public or private company?

89bio is a public company. It is classified as corporate owned and is currently acquired.

When was 89bio founded?

89bio was founded in 2018. It employs 101 to 250 people.

Where is 89bio based?

89bio is headquartered in San Francisco, United States, in the North America region.

How does 89bio make money?

One revenue line is on record: biopharmaceutical Product Revenue.

Who are 89bio's main competitors?

Direct peers on record are Inventiva, Madrigal Pharmaceuticals, Viking Therapeutics and Akero Therapeutics. Broad incumbents are Novo Nordisk, Eli Lilly, Boehringer Ingelheim (with Zealand Pharma) and Pfizer. Emerging players are Terns Pharmaceuticals and Galmed Pharmaceuticals.

Does 89bio have an API?

No public API is recorded for 89bio.

What industry is 89bio in?

89bio's product category is Biopharmaceutical Therapeutics. Its primary akta.pro industry code is HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity), with a secondary code of HLAAAAAH, Therapeutic Peptides & Protein/Peptide Biologics. Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
citybizNewleos Appoints Former 89bio CEO Rohan Palekar as Board ChairmanNewleos Therapeutics appointed Rohan Palekar, a veteran biotechnology executive, as Board Chairman, succeeding Christoph Westphal who had served as executive chairman since the company's founding in 2025. Palekar brings more than 30 years of industry experience, most recently serving as founding CEO of 89bio, which was acquired by Roche in 2025 in a transaction valued at up to $3.5 billion. The leadership transition comes as Newleos advances clinical-stage oral small-molecule therapies for neuropsychiatric disorders including anxiety, substance use disorders, and cognitive impairment, with the company approaching key clinical milestones in its anxiety trials.FinancialContent Business PageNewleos Names Rohan Palekar as Board ChairmanNewleos Therapeutics appointed Rohan Palekar, former CEO of 89bio, as Chairman of its Board of Directors, with Christoph Westphal stepping down from the Executive Chairman role but remaining on the board. Palekar led 89bio from inception through Phase 3 development before the company was acquired by Roche for up to $3.5 billion in 2025. He brings over 30 years of biotech industry experience to guide Newleos through key clinical inflection points in its ongoing anxiety trials.PR NewswireNASH Treatment Market Accelerates as Rezdiffra and Wegovy Establish Fibrosis-Defined Drug Pathways, Says Strategic Market ResearchThe global NASH treatment market is projected to grow from USD 8.75 billion in 2025 to USD 46.87 billion by 2032, a CAGR of 27.1%. Growth depends on fibrosis-confirmed patients, with Rezdiffra and Wegovy establishing approved pathways. Late-stage pipelines from Eli Lilly and others may add treatment options.GlobesIsrael missing out on global life sciences recoveryIsrael's life sciences sector stagnated in 2025, with investment falling to $1.4 billion from $2 billion in 2024. The report, from IATI and the Israel Innovation Authority, shows a decline in medical devices and public market offerings, though the 89bio sale to Roche for $2.4 billion offsets some losses.Labiotech.euRoche's strategy to reinvent its pipelineRoche is reinventing its pipeline with bets on obesity, IBD, and allogeneic cell therapy, including a $7.1 billion acquisition of Telavant and a $2.7 billion deal for Carmot. Its obesity lead CT-388 showed 22.5% weight loss in phase 2, but phase 3 trials face competition from Lilly and Novo Nordisk. Roche also faces Merck's earlier phase 3 results in IBD.BioSpaceRA Capital Looks to China for Next Startup To Put on SPAC Track to NasdaqRA Capital Management filed with the SEC on Tuesday to launch a new SPAC called Research Alliance III, seeking up to $57.5 million to acquire a life science startup, with explicit interest in Chinese biotech companies. The firm has a track record of successful SPAC deals, including merging Research Alliance I with POINT Biopharma in 2021, which later was acquired by Eli Lilly for $1.4 billion, and its portfolio includes 89bio (acquired by Roche for $3.5 billion) and Aktis Oncology (IPO'd for $318 million). The move aligns with a broader industry trend where Western pharmaceutical companies have ramped up partnerships with Chinese biotechs, including Novartis' $1.5 billion deal with SciNeuro and AstraZeneca's $2 billion investment in Jacobio Pharma.Roche[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2025 results with 7% sales growthRoche reported full-year 2025 sales of CHF 61.5 billion, representing 7% growth at constant exchange rates, driven by strong demand for pharmaceuticals and diagnostic solutions. The Pharmaceuticals Division grew 9% with key drugs Phesgo, Xolair, Ocrevus, Hemlibra, and Vabysmo collectively generating CHF 21.4 billion, while core operating profit increased 13% and IFRS net income rose 58%. The company also announced multiple regulatory approvals, positive clinical trial results across its pipeline, completed the acquisition of 89bio, and projects mid single-digit sales growth for 2026.Castle PlacementTop 10 Pharma Drug Discovery Delivery Capital Raises and Investors in the U.S.Castle Placement compiled a summary of pharma drug discovery delivery capital raises and acquisitions in the U.S. for October 16th – November 15th, 2025, featuring multiple significant transactions. Major acquisitions included Pfizer's $10 billion purchase of Metsera, Roche's $1.324 billion acquisition of 89bio, and AbbVie's $1.2 billion purchase of Gilgamesh Pharmaceuticals. Development capital was raised through private placements by Summit Therapeutics ($500 million) and Tharimmune ($545 million), while venture funding rounds included Braveheart Bio ($185 million Series A), NewLimit ($130 million Series B), Iambic ($99.27 million Series B3), Corner Therapeutics ($58.51 million Series A), and MarvelBiome ($39.56 million through combined Series C rounds).PharmaLiveU.S. tariff and pricing reforms drive pharma localization and spur outsourcing-led investment shiftsU.S. tariff and pricing reforms are driving pharmaceutical companies to localize manufacturing and pursue outsourcing-led strategies, exemplified by Pfizer's acquisition of Metsera and Roche's purchase of 89bio. The Trump administration is enforcing new policies, including a 100% tariff on patented drug imports effective October 2025 and Most-Favored-Nation pricing agreements, to boost domestic production. Consequently, contract development and manufacturing organizations (CDMOs) like Axplora Group are expanding capacity to meet the shifting regulatory and supply chain demands.GlobeNewswireRoche purchases shares in tender offer for 89bio, IncRoche's subsidiary accepted all validly tendered shares in its tender offer for 89bio at $14.50 per share plus a CVR for up to $6.00 per share. Approximately 94.1 million shares, representing 60.49% of outstanding stock, were tendered. Roche plans to complete the merger without a stockholder vote.